Wigan Ophthalmic Solution 0.2%+0.5%
Wigan Ophthalmic Solution 0.2%+0.5% Uses, Dosage, Side Effects, Food Interaction and all others data.
| Trade Name | Wigan Ophthalmic Solution 0.2%+0.5% |
| Generic | Brimonidine Tartrate + Timolol Maleate |
| Weight | 0.2%+0.5% |
| Type | Ophthalmic Solution |
| Therapeutic Class | Drugs for miotics and glaucoma |
| Manufacturer | Healthcare Pharmaceuticals Ltd. |
| Available Country | Bangladesh |
| Last Updated: | October 19, 2023 at 6:27 am |
Uses
This eye drop is indicated for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.Dosage
Wigan Ophthalmic Solution 0.2%+0.5% dosage
Instill 1 drop in the affected eye(s) twice daily.Side Effects
The most common side effects are allergic conjunctivitis, conjunctival folliculosis, conjunctival hyperaemia, eye pruritus and ocular burning or stinging.Precaution
Like other topically applied ophthalmic agents, it may be absorbed systemically. Due to the presence of Timolol, the same types of cardiovascular and pulmonary adverse reactions as seen with systemic beta-blockers may occur. Cautions should be exercised in treating patients with severe or unstable and uncontrolled cardiovascular or pulmonary diseases.Interaction
Specific drug interaction studies have not been conducted.Pregnancy & Breastfeeding use
There are no adequate and well-controlled studies in pregnant women. Combipres should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Timolol has been detected in human milk but it is not known whether Brimonidine Tartrate is excreted in human milk. A decision should be made whether to discontinue nursing or to discontinue taking into account the importance of the drug to the mother.Contraindication
Contraindicated in patients with hypersensitivity to any component of this product. Also contraindicated in bronchial asthma, severe chronic obstructive pulmonary disease, sinus bradycardia, second or third-degree atrioventricular block, overt cardiac failure and cardiogenic shock.Special Warning
Use in children: Safety and effectiveness in children below the age of 2 years have not been established.Use in elderly patients: No overall differences in safety or effectiveness have been observed between elderly and other adult patients.Acute Overdose
There have been reports of inadvertent overdosage with Timolol Ophthalmic Solution resulting in systemic effects similar to those seen with systemic beta-adrenergic blocking agents such as dizziness, headache, shortness of breath, bradycardia, bronchospasm, and cardiac arrest.Storage Condition
Store at a cool & dry place, protect from light. Do not use longer than 30 days after the first opening of the bottle. Keep out of the reach of children.Innovators Monograph
You find simplified version here Wigan Ophthalmic Solution 0.2%+0.5%
